Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
Open Access
- 31 July 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0200568
Abstract
Treatment of GT3 remains challenging compared to other genotypes. To explore real life SVR rates and to identify predictors of virological failure across the most recently used Direct acting antiviral (DAA) regimens in a large cohort of Italian patients with cirrhosis or advanced fibrosis (F3 or F4). Between May 2015 and June 2017, the combinations of sofosbuvir (SOF) plus daclatasvir (DCV) ± RBV and SOF plus velpatasvir (VEL) ± RBV become available in our Country. Patients were treated following Italian guidelines within a protocol implemented by 11 centers working together on genetics. Of 336 patients, 38.1% were Peg/IFN-experienced. SOF/DCV was used in 65.1%, SOF/VEL in the remaining. Overall SVR12 was 90.2% ranging from 87.2% after SOF/DCV to 95.7% after SOF/VEL (p = 0.012). No additional benefits of RBV use were observed for both regimens. 155 patients (46.1%) had cirrhosis. SVR12 was 87.1% (135/155) for cirrhotic patients and 92.8% (169/182) for non-cirrhotic (p = 0.09). NS5A-RASs were present at baseline in 6.4% of patients, PNPLA3GG and IL28BCC genotypes in 7.3% and 33.0%, respectively. No association between favorable genetics and SVR12 was observed. Predictors of relapse were: history of Peg/IFN/RBV failure (OR = 6.34, 95% CI 2.04–19.66, P = .001), baseline NS5A-RASs (OR = 8.7, 95% CI 1.58–47.92, P = 0.013) and treatment regimen (OR = 5.57 95% CI 1.64–18.95.96, P = 0.006). Our real-world results validate the efficacy of current GT3 IFN-free regimens suggesting that, among patients with severe disease, Peg/IFN/RBV experience and NS5A associated RASs are predictors of relapse. Their relevance can be expected to decline with the use of SOF/VEL. (250).Keywords
Funding Information
- IRCCS Casa Sollievo della Sofferenza (RC2017)
This publication has 27 references indexed in Scilit:
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisNew England Journal of Medicine, 2015
- Is genotype 3 of the hepatitis C virus the new villain?Hepatology, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3New England Journal of Medicine, 2014
- HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCVHepatology, 2014
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver DiseaseJournal of Biological Chemistry, 2011
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991